Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£9.96
|
611.43%
|
£498,000.00
|
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£75.21
|
330.51%
|
£301,356.62
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£103.44
|
184.57%
|
£199,196.71
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£9.23
|
172.27%
|
£190,589.96
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£30.95
|
105.65%
|
£143,953.49
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£103.44
|
82.42%
|
£127,692.44
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£35.70
|
7.01%
|
£74,910.07
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£103.44
|
1.72%
|
£71,204.64
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£3.90
|
-1.27%
|
£69,113.92
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£1.74
|
-9.37%
|
£63,437.50
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£103.44
|
-15.73%
|
£58,988.19
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£103.44
|
-18.85%
|
£56,808.41
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£24.28
|
-19.28%
|
£56,502.66
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£103.44
|
-23.18%
|
£53,770.98
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£35.70
|
-25.31%
|
£52,280.34
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£35.70
|
-35.03%
|
£45,477.71
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£1,516.00
|
-43.39%
|
£39,626.59
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£138.00
|
-56.88%
|
£30,187.50
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£48.00
|
-57.14%
|
£30,000.00
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.60
|
-59.18%
|
£28,571.43
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£4.26
|
-59.89%
|
£28,079.10
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£39.56
|
-64.67%
|
£24,729.42
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£1.19
|
-65.80%
|
£23,936.78
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£138.00
|
-77.47%
|
£15,768.85
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£16.76
|
-83.44%
|
£11,592.89
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£0.17
|
-84.13%
|
£11,105.77
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.39
|
-84.15%
|
£11,097.56
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£1.80
|
-85.00%
|
£10,500.00
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£5.00
|
-89.16%
|
£7,590.54
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£1.28
|
-89.88%
|
£7,083.00
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£2.12
|
-92.93%
|
£4,946.67
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£1.18
|
-94.43%
|
£3,896.23
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.